Recent studies have described that pirfenidone, a drug approved for IPF treatment reduces mRNA expression of mmp3 in a profibrotic model of human lung fibroblasts stimulated by TGF-β1 [100]. This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.